Gates Foundation’s $40m Incentivizes Cancer Specialist Immunocore To Develop TB, HIV Drugs
Executive Summary
Oxford, UK-based Immunocore, which is developing immunotherapies against cancer, has secured $40m in funding from the Bill & Melinda Gates Foundation to boost its research activities in infectious diseases. The company hopes to develop novel therapeutics to reduce treatment timelines and improve outcomes for patients with HIV and TB.
You may also be interested in...
Immunocore Expands IO Pact With Genentech To Target MAGE-A Antigens
Genentech and Immunocore will now co-develop the biotech's therapeutic candidate IMC-C103C, an ImmTAC molecule targeting tumors that express melanoma-associated antigen A4.
Interview: Immunocore Gets Ready To Go To Market
The first molecule from its collaboration with GSK has just gone into Phase I trials but Immunocore CEO Andrew Hotchkiss tells Scrip that the UK biotech unicorn is also preparing for the launch of its own lead candidate, IMCgp100 for uveal melanoma.
Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms
Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.